Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells

Experimental and Molecular Medicine

Volumn 43, Issue 12, 2011, Pages 684-692

  Jeong, In Kyung ^a   Oh, Da Hee ^a   Park, Seung Joon ^b   Kang, Ja Heon ^a   Kim, Sunshin ^c   Lee, Myung Shik ^d   Kim, Myung Jun ^e   Hwang, Yoo Chul ^a   Ahn, Kyu Jeong ^a   Chung, Ho Yeon ^f   Chae, Min Kyung ^f   Yoo, Hyung Joon ^f  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c National Cancer Center   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Hallym University   (South Korea)

Author keywords

Cell proliferation; Glucose metabolism disorders; Muscle; NF B; Plasminogen activator inhibitor 1; Smooth; Vascular

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GLUCOSE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLIDINE DITHIOCARBAMATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; RATTUS;

EID: 84855161933     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2011.43.12.079     Document Type: Article

References (37)

1. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97:1715-22
2. Brand K, Page S, Walli AK, Baeuerle PA. Role of nuclear factor-κB in atherosclerosis. Exp Physiol 1997;82:297-304
3. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 2002;105:633-8
4. Chen Y, Budd RC, Kelm RJ Jr, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 2006;26:1777-83
5. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 2008;201:248-57
6. Diebold I, Kraicun D, Bonello S, Görlach A. The 'PAI-1 paradox' in vascular remodeling. Thromb Haemost 2008; 100:984-91
7. Erl W, Hannson GK, de Martin R, Draude G, Wever KSC, Weber G. Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis proteon-1 expression in vascular smooth muscle cells. Circ Res 1999;84:668-77
8. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997;350:SI9-I13
9. Gerstein HC, Anand S, Yi QL, Vuksan V, Lonn E, Teo K, Malmberg K, McQueen M, Yusuf S; SHARE Investigators. The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. Diabetes Care 2003;26:144-9
10. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001;104:503-16
11. Hattori Y, Hattori S, Sato N, Kasai K. High glucose-induced nuclear factor κB activation in vascular smooth muscle cells. Cardiovas Res 2000;46:188-97
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
13. Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999;56:104-32
14. Jeong IK, King GL. New perspectives on diabetic vascular complications: the loss of endogenous protective factors induced by hyperglycemia. Diabetes Metab J 2011;35:8-11
15. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK, Park JY, Lee KU, Kim JG, Lee IK. Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity. Exp Mol Med 2007;39:106-13
16. Konstantinides S, Schäfer K, Loskutoff DJ. Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. Arterioscler Thromb Vasc Biol 2002;22:1943-5
17. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 1997;151:1085-95
18. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005;434:1138-43
19. Lenardo MJ, Baltimore D. NF-κB: a pleiotropic mediator of inducible and tissue specific gene control. Cell 1989;58: 227-9
20. Lee CW, Lin CC, Lee IT, Lee HC, Yang CM. Activation and induction of cytosolic phospholipase A2 by TNF-α mediated through Nox2, MAPKs, NF-κB, and p300 in human tracheal smooth muscle cells. J Cell Physiol 2011;226:2103-14
21. Lee KM, Seo HY, Kim MK, Min AK, Ryu SY, Kim YN, Park YJ, Choi HS, Lee KU, Park WJ, Park KG, Lee IK. Orphan nuclear receptor small heterodimer partner inhibits angiotensin II-stimulated PAI-1 expression in vascular smooth muscle cells. Exp Mol Med 2010;42:21-9
22. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-46
23. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000;283:221-8
24. Meilhac O, Ho-Tin-Noé B, Houard X, Philippe M, Michel JB, Anglés-Cano E. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J 2003;17:1301-3
25. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004;61:671-82
26. Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore A, Pellegrini G, Vitacolonna E, Capani F, Consoli A. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001;21:1378-82
27. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
28. Ruiz E, Gordillo-Moscoso A, Padilla E, Redondo S, Rodriguez E, Reguillo F, Briones AM, van Breemen C, Okon E, Tejerina T. Human vascular smooth muscle cells from diabetic patients are resistant to induced apoptosis due to high Bcl-2 expression. Diabetes 2006;55:1243-51
29. Selzman CH, Shames BD, McIntyre RC Jr, Banerjee A, Harken AH. The NFkappaB inhibitory peptide, IkappaBalpha, prevents human vascular smooth muscle proliferation. Ann Thorac Surg 1999;67:1227-31
30. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996;383:441-3
31. Suzuki M, Akimoto K, Hattori Y. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sci 2002;72:59-66
32. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
34. Wu J, Peng L, McMahon GA, Lawrence DA, Fay WP. Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009;29: 1565-70
35. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999;48:855-64
36. Yoo HJ, Kozaki K, Akishita M, Watanabe M, Eto M, Nagano K, Sudo N, Hashimoto M, Kim S, Yoshizumi M, Toba K, Ouchi Y. Augmented Ca2+ influx is involved in the mechanism of enhanced proliferation of cultured vascular smooth muscle cells from spontaneously diabetic Goto-Kakizaki rats. Atherosclerosis 1997;131:167-75
37. Yoon SJ, Yoon YW, Lee BK, Kwon HM, Hwang KC, Kim M, Chang W, Hong BK, Lee YH, Park SJ, Min PK, Rim SJ. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009;41:802-11